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Abstract
Epigenetic programming is essential for lineage differentiation, embryogenesis and placenta-
tion in early pregnancy. In epigenetic association studies, DNA methylation is often examined
in DNA derived from white blood cells, although its validity to other tissues of interest remains
questionable. Therefore, we investigated the tissue specificity of epigenome-wide DNA
methylation in newborn and placental tissues. Umbilical cord white blood cells (UC-WBC,
n= 25), umbilical cord blood mononuclear cells (UC-MNC, n= 10), human umbilical vein
endothelial cells (HUVEC, n= 25) and placental tissue (n= 25) were obtained from 36 uncom-
plicated pregnancies. Genome-wide DNA methylation was measured by the Illumina
HumanMethylation450K BeadChip. Using UC-WBC as a reference tissue, we identified
3595 HUVEC tissue-specific differentially methylated regions (tDMRs) and 11,938 placental
tDMRs. Functional enrichment analysis showed that HUVEC and placental tDMRs were
involved in embryogenesis, vascular development and regulation of gene expression. No
tDMRs were identified in UC-MNC. In conclusion, the extensive amount of genome-wide
HUVEC and placental tDMRs underlines the relevance of tissue-specific approaches in future
epigenetic association studies, or the use of validated representative tissues for a certain disease
of interest, if available. To this purpose, we herewith provide a relevant dataset of paired,
tissue-specific, genome-wide methylation measurements in newborn tissues.
Introduction
Adverse influences during early prenatal development are associated with an increased risk of
cardiovascular, metabolic and neurodevelopmental dysfunction in child- and adulthood which
is in line with the ‘Developmental Origins of Health and Disease’ paradigm1. These associations
are potentially mediated by epigenetic mechanisms1. Epigenetic reprogramming is essential
during early embryonic development and placentation, when active and passive demethylation
takes place immediately after fertilisation, followed by de novo methylation at the late morula
stage2,3.
Epigenetic epidemiological studies are essential to elucidate the role of DNA methylation of
embryonic and extra-embryonic tissues, in the associations between prenatal exposures and
health or disease in later life. Most studies, however, focus on DNA methylation levels in white
blood cells as surrogate tissue because the target tissue of interest is not easily accessible in
human studies4. In 1983, it was demonstrated in rodents and followed by many other studies
that DNA methylation is established in a tissue-specific manner and as such accompanies
lineage differentiation5–7. Recently, this has been addressed in epigenome-wide analyses of
DNA methylation with attempts to identify differentially methylated positions (DMPs) and
differentially methylated regions (DMRs) associated with tissue specificity or disease8–14.
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To further examine tissue specificity in this context, DNA
methylation is best studied in newborn tissues such as placental
tissue and umbilical cord (blood), since postnatal environmental
exposures affecting DNA methylation can be excluded15. The pla-
centa represents an essential extra-embryonic organ for embryonic
and fetal growth and development. The epigenetic programming of
the placenta is involved in the regulation of fetal demands and
intrauterine conditions16. To examine the newborn vasculature
as target tissue of linking prenatal exposure to future vascular
health, human umbilical vein endothelial cells (HUVEC) are the
best accessible representative tissue, and no prior genome-wide
methylation studies have been performed in HUVEC before.
During initial embryonic development and differentiation, the
development of these cells is also highly regulated by various epi-
genetic mechanisms, influenced by external exposures and the
local haemodynamic conditions of the pregnancy17–19. One of
the challenges of whole blood epigenetic studies is the variation
in blood cell mixtures as potential confounder for DNA methyla-
tion differences20. This can be investigated by comparing DNA
methylation levels between umbilical cord white blood cells
(UC-WBC) and a subgroup without granulocytes: umbilical cord
blood mononuclear cells (UC-MNC).
Against this background, the objective of this study was to exam-
ine the tissue specificity of epigenome-wide DNA methylation of
450,000 methylation sites in placental tissue, HUVEC and UC-
MNC, in comparison to the widely used UC-WBC as representative
tissue, in order to ultimately increase the use of validated represen-
tative tissues for diseases of interest in future epigenome-wide
association studies (EWAS). Although the genome-wide Illumina
450K array covers a relatively small fraction of the genome
compared to high-resolution techniques, the regions measured
are biologically informative and relevant for the surrounding
genome biology, and larger sample size measurements are possible.
Methods
Study design
Pregnant women and their newborn babies were recruited between
June 2011 and June 2013 in a nested case-control study embedded
in the Rotterdam Periconceptional Cohort (Predict Study), at
the Erasmus MC, University Medical Centre Rotterdam, The
Netherlands21.
Maternal and newborn characteristics
The case-control study aimed to examine genome-wide DNA
methylation in pregnancies with various pregnancy-induced dis-
eases. For the current study, we utilised 36 uncomplicated control
pregnancies, from which data were generated for up to 25 cases per
tissue type, as depicted in Fig. 1. Uncomplicated pregnancies were
defined as pregnancies without the following pregnancy-specific
complications: preeclampsia, gestational hypertension, fetal
growth restriction or preterm birth. Women with HIV infection,
those aged <18 years, those not able to read or understand the
Dutch language, multiple birth pregnancies or women with preg-
nancies complicated by fetal congenital malformations were
excluded. Due to the tertiary hospital setting where the study
was carried out, chronic comorbidities, including endocrine, met-
abolic, autoimmune, renal or cardiovascular diseases, were not
exclusion criterion. None of the woman smoked during pregnancy.
Maternal and newborn characteristics were obtained from hospital
medical records. All women gave written informed consent before
participation, and parental informed consent was obtained for the
child. All methods were performed in accordance with the princi-
ples expressed in the Declaration of Helsinki, and ethical approval
for the study was given by the Erasmus MC, University Medical
Centre Research Ethics Board (MEC-2004-227).
Data collection
Umbilical cord blood (UCB) samples from the umbilical vein were
collected with the placenta still in situ. Thereafter, placental tissue
was obtained, and HUVEC were isolated and stored until DNA
extraction. A detailed description of the data collection,
UC-WBC and UC-MNC processing, HUVEC isolation and
DNA extraction is provided in Appendix 1.
DNA methylation measurement
Isolated genomic DNA (500 ng) was treated with sodium bisul-
phite using the EZ-96 DNA methylation kit (Shallow) (Zymo
Research, Irvine, CA, USA). Hybridisation was performed follow-
ing manufacturer’s instructions. DNA methylation of cytosine
guanine dinucleotides (CpGs) was measured by the Illumina
HumanMethylation450K BeadChip using the manufacturer’s
protocol (Illumina, Inc., San Diego, CA, USA)22–24.
Data quality control and pre-processing
All data pre-processing and statistical analyses were performed in
R software version 3.2.2 and Bioconductor version 3.125. A quality
control protocol was conducted in Illumina GenomeStudio soft-
ware using the methylation module. It included a sample call rate
check, colour balance check and control dashboard checks. Probes
targeting a CpG with documented single-nucleotide polymor-
phisms in the C or G nucleotides were removed (n= 17,196)
(minor allele frequency >0.05, European population, 1000
Genomes Project). Probes directed at the sex chromosomes
(n= 11,648) and with a detection of p-value >0.01 in more than
Fig. 1. Flow chart of the sample distribution in the study population. UC-WBC, umbili-
cal cord blood white blood cells; UC-MNC, umbilical cord blood mononuclear cells;
HUVEC, human umbilical vein endothelial cells.
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1% of samples (n= 2773) were also excluded. Out of 485,512
probes, a total of 454,892 were left for further analysis.
Normalisation was performed for all samples together by the
Dasen method, which consists of background adjustment and
between-array normalisation, applied to Type I and Type II probes
separately (Bioconductor package watermelon version 1.80)26. The
effect of the Dasen normalisation procedure was checked by
plotting raw and normalised density plots per tissue, where the
β-values with and without Dasen normalisation showed a very
high correlation (r> 0.99, Supplementary Fig. S1).
tDMP identification
Methylation β-values were converted to M-values to achieve a
normal distribution of the data using M-value = log2 (β-value/
(1 − β-value))27. M-values were used for all statistical analyses,
whereas β-values were depicted in the presentation of our data
for a better biological understanding. For every CpG on the array,
we estimated a linear mixed model with the M-value as response,
tissue as categorical predictor and a random intercept for each
subject, adjusted for bisulphite plate batch and gestational age
to compare each tissue with the UC-WBC (R package ‘lme4’)28.
Sensitivity analyses were performed for the following covariates:
batch effect of the bisulphite plate, gestational age, birth weight,
fetal sex, comorbidity andmoment of inclusion for the study in or
>1st trimester. Only gestational age and bisulphite plate were
thereafter included in our statistical model as potential confound-
ers. The effect of all potential technical and biological covariates
on the methylation β-values is depicted in a correlation heatmap
(Supplementary Fig. S2). It is demonstrated that the first three
principle components are represented by the different
tissues, explaining 98.7% of total variation present in our data.
We additionally checked whether adjustment for variation in
underlying cell populations in UC-WBC and placenta demon-
strated an effect on our model. For this, we rerun our final model
with additional covariates representing the first two principle
components of imputed blood cell populations and imputed
placental underlying cell variation using Houseman’s data20,29.
These additional covariates were not applied to our final model
due to the very strong correlation that was demonstrated between
the two models in HUVEC (r = 0.996) and placental samples
(r = 0.998). The correlation in the UC-MNC samples is lower
due to the initial very low tissue effect in this comparison, which
is attenuated after correction for the different blood cell popula-
tions in UC-WBC (r = 0.770) (Supplementary Fig. S3). The
potential effect of ‘mode of delivery’ was also excluded after com-
paring our final statistical model with and without additional
covariate ‘mode of delivery’ (vaginal delivery versus caesarean
section) and observing a very strong correlation between the
two models in UC-MNC (r = 0.95), HUVEC (r > 0.99) and
placental samples (r > 0.99) (Supplementary Fig. S4).
We used the following model:
Mij ¼ bi þ β0 þ β1THUVEC þ β2TPLACENTA þ β3TUC-MNC þ β4GA
þ β5PLATE2 þ β6PLATE3 þ "ij:
Mij is the logit of the methylation of individual i in tissue j,
where j is UC-WBC, UC-MNC, HUVEC or placenta. bi is the
subject-specific intercept which is assumed to follow a normal dis-
tribution, THUVEC, TPLACENTA and TUC-MNC are tissue-specific
indicator variables, GA is the gestational age, and PLATE2 and
PLATE3 are indicator variables for the sample plates. β0 Is the
intercept, and β1 to β7 are the regression coefficients indicating
the effect of the various covariates. ϵij is the measurement error,
assumed to be independently normally distributed with a constant
variance and mean of zero. All tissues were compared against one
reference tissue: UC-WBC.
A false discovery rate (FDR)-adjusted p-value below 0.05 was
considered significant. CpG sites were classified as tissue-specific
differentially methylated position (tDMP), if statistically signifi-
cant and presenting with a minimal effect size ΔM of 1.3 versus
UC-WBC. We considered various M-value cut-off values for fur-
ther data analysis and applied the widely used robust cut-off of 1.3
ΔM-value (~20% on β-value scale)30 (Supplementary Table S1 and
Supplementary Fig. S5). For the comparison with the smallest
number of samples (n= 10 UC-WBC samples), we were able to
measure methylation differences of at least 9.4% Δβ, with a power
of 0.7 (SD of 0.05 and p< 0.05). The lambda-values for the differ-
ent epigenome-wide analysis performed include 0.02 for UC-WBC
versus UC-MNC, 6.4 for UC-WBC versus HUVEC and 76.6 for
UC-WBC versus placenta. These values are to be expected looking
at the amount of CpGs that were found significantly different and
based on the underlying biology of our study samples.
A partial replication was performed by a correlation analysis
between the estimates (β) for the tissue effect in our dataset with
the Δβ of three publicly available Gene expression Omnibus
(GEO) datasets for UC-WBC (GSE69176: n= 152 samples),
HUVEC (GSE82234: n= 6 samples) and placental tissue
(GSE75248: n= 174 samples with adequate gestational age
range)31,32. Δβ was calculated as the Δβ mean methylation of
HUVEC or placenta versus UC-WBC for all our tDMPs
(Supplementary Fig. S7). To check the reproducibility of our
tissue-specific differentially methylated regions (tDMRs), we com-
pared our results to three previous EWAS with available tDMR
datasets and similar study designs with respect to type of methyla-
tion array and tissues.We were able to compare our tDMR genes in
HUVEC to tDMR genes in vascular tissue of Lokk et al., our tDMR
genes in placenta to amniotic tDMR genes of Slieker et al. 2015
(both extra-embryonic tissues), and all our tDMR genes in
HUVEC and placenta to those of Slieker et al. 2013 using the online
Jvenn tool9,10,33,34 (Supplementary Table S2).
CpG density and gene-centric enrichment analysis of tDMPs
tDMPs were annotated according to their position relative to CpG
islands and relative to genes using UCSC database. In relation to
CpG islands, we identified CpG shores as the 2-kb CpG island
flanking region and shelves as the 2-kb CpG shore flanking
region. Remaining tDMPs were annotated as non-CpG island
regions9. Enrichment analysis was applied to tDMPs. Relative to
genes, tDMPs were annotated as gene body (þ500 bp to 3’ end
of the gene), distal promotor (>10 to 1.5 kb from the nearest tran-
scription start site (TSS)), proximal promotor (−1.5 to þ500 bp
from the nearest TSS), intergenic (>10 kb from the nearest
TSS), and downstream regions (3’ end to þ5 kb from 3’ end).
Human genome build 37 was used for all annotations.
tDMR identification
tDMRs were generated according to a previously published algo-
rithm as regions in which at least three tDMPs were detected with
an inter-CpG distance ≤1 kb and not interrupted by more than
three non-DMPs within the DMR (DMRfinder)9.
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Gene Ontology term enrichment analysis and Ingenuity
Pathway Analysis of tDMR genes
HUVEC and placental tDMRs were mapped to the nearest gene
based on Ensembl annotations from UCSC, also when facing
multiple genes. Assigned Ensembl genes were uploaded to the
Database for Annotation, Visualization and Integrated
Discovery (DAVID) tool to examine possible enrichment of cor-
responding gene ontology (GO) terms using the GO_BP_FAT
annotation category (DAVID Bioinformatics Resources 6.7)35,36.
Fisher Exact was applied to measure the gene enrichment of anno-
tated GO terms of the uploaded gene list, against the whole human
genome list as a background. To focus on the biology of the anno-
tated GO terms, clusters of similar annotations were examined
from the DAVID Functional Annotation Clustering table tool.
The clustering algorithm is based on the hypothesis that similar
annotations have similar gene members, resulting in a group
enrichment score to rank their biological significance.
We additionally conducted Ingenuity Pathway Analysis (IPA)
with the annotated DMP Ensembl gene lists to validate the DAVID
enrichment and focused on canonical pathways and networks.
Associated canonical pathways were subjected to Benjamini–
Hochberg procedure for controlling FDR (p< 0.05). Networks
were generated based on network eligible molecules, which were
encoded by our DMP genes and also interact with other molecules
in the Ingenuity Pathways Knowledge Base. A high score for a
network indicates a more approximate fit between network eligible
molecules and the molecules that constitute the network, calcu-
lated using the right-tailed Fisher’s exact test.
Results
Tissues from 36 uncomplicated control pregnancies were studied,
derived from a nested case-control study embedded in the
Rotterdam Periconceptional Cohort21. From a large majority of
22 pregnancies, we obtained isogenic UC-WBC, HUVEC and pla-
cental samples, and in four pregnancies, one or two tissues were
obtained. Nine pregnancies provided UC-MNC samples only.
This resulted in 25 UC-WBC, 10 UC-MNC, 25 HUVEC and 25
placental samples (Fig. 1).
Maternal and newborn characteristics of the four tissue groups
are shown in Table 1 and were overall comparable. The mean age
of the women was 32 years and 83% were of Western geographic
origin. Newborns were born at a mean gestational age of 40 weeks
and 58% were male. In the UC-MNC tissue group, comorbidity
was present in 10% of the pregnancies and the mean newborn
birth weight was 3352 g versus the other tissue groups presenting
with comorbidity in 24% to 28% and a mean birth weight
around 3800 g.
tDMP identification
Genome-wide DNA methylation data revealed an overall bimodal
distribution (Supplementary Fig. S6). In UC-WBC, UC-MNC and
HUVEC, only a small amount of CpGs demonstrated methylation
levels around 50%, in contrast to a relatively large amount of CpGs
with around 50% methylation in placental tissue. Most annotated
regions demonstratedmedian methylation levels between 50% and
85%, except for CpG islands and proximal promotor regions,
which revealed lower median methylation levels of around 10%,
(Supplementary Table S3).
A heatmap based on the clustering of methylation according to
CpG and sample revealed clustering of the three different tissues
(UCB, HUVEC and placenta) (Fig. 2). No distinctive clusters
were identified for the two different UCB cell fractions. On an
epigenome-wide level, we identified tissue-specific CpG methyla-
tion using UC-WBC as reference tissue. We observed 1636 (0.4%)
differentially methylated CpGs between UC-WBC and UC-MNC,
193,945 (43%) between UC-WBC and HUVEC and 333,061 (73%)
between UC-WBC and placental tissue (all FDR-adjusted
p< 0.05). Those statistically differentially methylated CpGs with
an additional effect size >1.3 in M-value (corresponding to logit2
of the β-value: ~Δ 20% β-value) were defined as tDMPs. This
revealed 2 (4 × 10-6%) MNC-tDMPs, 49,979 (11%) HUVEC
tDMPs and 126,482 (28%) placental tDMPs, in comparison to
UC-WBC (Fig. 3a, Supplementary Table S1). We provided a
Table 1. Maternal and newborn characteristics of uncomplicated control pregnancies (n = 36)
UC-WBC (n= 25) UC-MNC (n= 10) HUVEC (n= 25) Placenta (n= 25) Overall (n= 36)
Maternal characteristics
Age (years) 31.8 (5.4) 32.1 (4.7) 31.9 (5.4) 31.8 (5.3) 31.8 (5.1)
Nulliparous, n (%) 7 (28.0) 3 (30.0) 8 (32.0) 8 (32.0) 11 (30.6)
Ethnicity, n (%)
Western geographic origin 20 (80.0) 9 (90.0) 20 (80.0) 20 (80.0) 30 (83.3)
Non-Western geographic origin 5 (20.0) 1 (10.0) 5 (20.0) 5 (20.0) 6 (16.7)
Preconceptional BMI (kg/m2) 24.9 (4.4) 23.4 (3.1) 24.9 (4.4) 24.7 (4.5) 24.3 (4.0)
Comorbidity (yes), n (%) 6 (24.0) 1 (10.0) 7 (28.0) 7 (28.0) 8 (22.2)
Newborn characteristics
Males, n (%) 14 (56.0) 5 (50.0) 16 (64.0) 14 (56.0) 21 (58.3)
Gestational age at birth* (weeks) 39.9 (1.9) 39.8 (1.9) 39.9 (1.7) 39.9 (1.9) 39.7 (1.1)
Birth weight (g) 3815 (396) 3352 (377) 3811 (364) 3788 (398) 3691 (418)
BMI, body mass index; UC-WBC, umbilical cord white blood cells; UC-MNC, umbilical cord blood mononuclear cells; HUVEC, human umbilical vein endothelial cells.
Data are presented as mean (standard deviation) or number (%).
*Non-parametric data are presented as median (interquartile range). No statistical testing has been performed due to overlapping pregnancies between the tissue groups.
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Supplementary Table with all tDMPs observed in UC-MNC,
HUVEC and placenta, including CpG identifiers, β-values and
p-values (Supplementary Table S2). A partial replication demon-
strated a strong correlation between the estimates (β) for the tissue
effect in our own dataset and the Δβ methylation differences of
HUVEC and placenta versus UC-WBC of three independent data-
sets for all our tDMPs (r= 0.94 in HUVEC samples and r= 0.98 in
placental samples, p< 0.0001) (Supplementary Fig. S7).
CpG density and gene-centric enrichment of tDMPs
To evaluate whether tDMPs were enriched in certain genomic
annotations, CpG island and gene-centric annotations of
HUVEC and placental tDMR genes were examined (Fig. 4,
Supplementary Table S4). tDMP annotation relative to CpG
islands showed that tDMPs were significantly enriched in CpG
shores, shelves and especially in non-CpG island regions (non-
CPG island odds ratio (OR)HUVEC 2.02, 95% confidence interval
(CI) 1.98–2.06, ORPlacenta 1.54, 95% CI 1.52–1.56) and strongly
depleted in CpG islands (CpG island ORH 0.47, 95% CI 0.47–
0.48, ORP 0.27, 95% CI 0.26–0.27). Both annotation patterns were
concordant for HUVEC and placental tDMPs.
tDMPs were significantly enriched in all gene-centric regions
except for a strong depletion of tDMPs in proximal promotors
(ORHUVEC 0.55, 95% CI 0.54–0.57, ORPlacenta 0.49, 95% CI 0.48–
0.50). The strongest placental enrichment was observed in inter-
genic regions. HUVEC’s strongest enrichment was observed in
gene bodies (Fig. 4, Supplementary Table S4).
A combined gene and CpG island annotation of tDMPs is
depicted in Supplementary Fig. S8. A prominent depletion of
tDMPs in proximal promotors due to a strong underrepresenta-
tion of tDMPs in CpG island proximal promotors was observed
Fig. 2. Heatmap based on clustering of methylation (β-value) of all differentially methylated CpGs. Samples are depicted on the horizontal axis and CpGs on the vertical axis.
Samples cluster by tissue type, without distinctive clustering for the two different UCB cell fractions. β-Values are depicted for a better biological understanding of the figure.
UC-WBC, umbilical cord white blood cells; UC-MNC, umbilical cord blood mononuclear cells; HUVEC, human umbilical vein endothelial cells.
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(ORPlacenta 0.21, 95% CI 0.21–0.22, ORHUVEC 0.12, 95% CI 0.11–
0.12). The combined annotation enrichment analysis also revealed
opposite annotation patterns for HUVEC and placental tDMPs,
mainly in various gene-centric regions situated in CpG islands
and CpG shelves.
tDMR identification
To obtain a more robust measure of genomic regions with a large
proportion of tissue-specific sites, we used the tDMPs to generate
tDMRs with DMRfinder. This revealed 3595 HUVEC tDMRs with
a mean length of 639 basepairs (bp) and 11,938 placental tDMRs
with a mean length of 894 bp. The numbers of overlapping
HUVEC and placental tDMRs are presented in Fig. 3b.
GO term enrichment of tDMR genes
To gain insight in tDMR functional categories, tDMRs were
mapped to their nearest gene. This yielded 2882 unique (without
duplicate genes) HUVEC genes and 7629 unique placental genes.
The 2882 HUVEC tDMR genes mapped to 2296 genes in DAVID
because the remaining annotations were mainly transcripts. The
2296 genes were enriched for involvement in embryogenesis, regu-
lation of gene expression, cell motility and vascular development.
The top 3000 placental tDMR genes were selected based on the
regions with the largest absolute mean value of each tDMP
M-value difference within the DMR, to meet the maximum num-
ber of genes for the Functional Annotation Clustering tool in
DAVID. After excluding transcripts, DAVID mapped 2208 pla-
cental tDMR genes and revealed enriched GO term involvement
in embryogenesis, regionalisation and regulation of gene
expression. HUVEC and placental highest significantly enriched
GO terms are presented in Table 2.
Qiagen IPA of tDMR genes
Ingenuity software mapped 2523 of the 2881 HUVEC tDMR genes
and identified enriched canonical pathways. Top-ranked pathways
were mainly involved in immune response processes. We further
conducted network analyses, using Fisher’s exact test, revealing
that the top networks were mainly associated with cellular func-
tion, movement and signalling, immune response and embryonic
development.
Out of 7629 placental tDMR genes, 6333 were mapped by
Ingenuity, demonstrating top five enriched pathways involved in
a broad spectrum of cell signalling processes and embryonic stem
cell pluripotency. The top networks were mainly associated with
cardiovascular disease, embryonic development and cellular move-
ment and function. The highest significantly enrichedHUVEC and
placental pathways and networks are presented in Table 3.
Discussion
This epigenome-wide DNA methylation study shows 43%
HUVEC- and 73% placental tissue-specific DNA methylation
out of all measured CpGs, in comparison to UC-WBC.
Enrichment of tDMPs was demonstrated in gene bodies and
non-CpG islands. No tDMRs were observed in UC-MNC com-
pared to UC-WBC.
The most pronounced identification of placental compared to
HUVEC tDMRsmight be explained by the time point of placental-
specific development. After fertilisation and global demethylation
Fig. 3. Venn diagram of the number of unique and overlapping
HUVEC and placental (a) tDMPs and (b) tDMRs, relative to UC-
WBC. tDMPs, tissue-specific differentially methylated positions;
tDMRs, tissue-specific differentially methylated regions; HUVEC,
human umbilical vein endothelial cells.
Fig. 4. HUVEC and placental tDMP enrichment in the (a) CpG density and (b) gene-centric annotation, in comparison to UC-WBC. (a) tDMP annotation relative to CpG islands
showed that tDMPs were significantly enriched in CpG shores, shelves and especially in non-CpG island regions and strongly depleted in CpG islands. Annotation patterns in
relation to CpG islands were concordant for HUVEC and placental tDMPs. (b) tDMP annotation relative to genes demonstrated that tDMPs were significantly enriched in all
gene-centric regions except for a strong depletion of tDMPs in proximal promotors. The strongest placental enrichment was observed in intergenic regions. HUVEC’s strongest
enrichment was observed in gene bodies. *p< 0.05. Non-CGI, non-CpG island; HUVEC, human umbilical vein endothelial cells.
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of the paternally and maternally derived genome, the very first
de novo DNA methylation at the late morula stage determines
the initial developmental lineage differentiation of the inner cell
mass that will give rise to the embryo and the trophectoderm that
will evolve into placental tissue. The inner cell mass methylation is
more pronounced than the relatively hypomethylated trophecto-
derm, resulting in an asymmetrical methylation status from this
developmental stage onwards, which is consistent with the
observed extent of genome-wide placental-specific methylation
and in line with previous studies2,3,33. The relatively hypomethy-
lated state of the trophectoderm is necessary for the highly prolif-
erative and invasive process of first trimester placentation
requiring an active transcription of genes3. Schroeder et al.
described partially methylated regions (PMRs) in the placenta,
characterised by methylation levels around 45%, in contrast to
most human tissues demonstrating mainly a high methylation
(>70%) of the majority of the genome37. This is in line with the
relatively abundant placenta-specific intermediate methylation
levels around 50% in our data and that of others, especially since
the PMRs were annotated to genes with tissue-specific functions12.
HUVEC displayed another substantial tissue-specific methyla-
tion pattern compared to UC-WBC, but less extreme than placental
tissue. This may be explained by the fact that HUVEC and the sur-
rounding umbilical cord originate from the inner cell mass38. UCB
originates from endothelial cells in the ventral aorta of the develop-
ing embryo during initial haematopoiesis and thus displays a more
common background with HUVEC, substantiating the less diverg-
ing methylation profiles of UC-WBC and HUVEC39. These obser-
vations in HUVEC suggest that carefully selected tDMR-poor
genomic regions may be represented adequately by UC-WBC in
terms of DNAmethylation in candidate gene studies, but this needs
further functional validation.
In comparison to peripheral blood, Slieker et al. identified
3500 DMRs in peripheral tissues and 5400 DMRs in post-mortem
internal tissues, mainly situated in CpG-poor regions, which is in
agreement with our data considering HUVEC tDMR quantity
and genomic occurrence9. Also in line with our observations
are the recently published data of Lowe et al. showing highly dis-
tinctive epigenome-wide methylation levels in whole blood DNA
versus several somatic tissues using publicly available Illumina
450K databases8,40. Although other studies have identified
tDMRs to examine tissue specificity, these studies are limited
in terms of comparability, due to the use of post-mortem tissues
or cultured cells and a wide variety of statistical approaches10,41,42.
There exists partial overlap between tDMRs identified in our
study and in previous EWAS. These potentially represent highly
tissue-specific sites throughout several different tissues and sug-
gest a certain degree of reproducibility of our results
(Supplementary Table S2).
We expected to find substantial differences in DNA methyla-
tion of the two blood cell fractions since DNA methylation is
important in haematopoiesis and blood cell differentiation, and
MNC represent a strongly different subgroup as they lack the larg-
est proportion of total WBC: granulocytes43. A genome-wide
profiling study using Illumina 27K Methylation arrays compared
haematopoietic pluripotent cells (HPC) with granulocytes and
monocytes from the same UCB and demonstrated that further
differentiation of HPC is associated with demethylation of certain
epigenetic programmes, depending on the cell type43. In our data,
however, only 0.4% of all epigenome-wide measured CpG sites
were statistically differentially methylated, resulting in only two
tDMPs and no tDMRs. This is partly explained by the decreased
power as a result of the 2.5 times lower UC-MNC sample size,
but mainly by the smaller effect sizes we find when studying the
UC-MNC group and the biological origin being much more sim-
ilar to the UC-WBC than the other tissues. Moreover, instead of
the HUVEC and placental samples that were genetically almost
identical, the MNC samples were in 90% non-genetically matched
to the UC-MNC, resulting in genetically driven differences that
overwhelm cell-specific differences when closely related cells are
compared. This, combined with the fact that not all probes asso-
ciated with single nucleotide polymorphisms were removed, and
the contribution of methylation quantitative trait loci – single
nucleotide polymorphisms, may explain the UC-MNC result. It
seems therefore equally adequate to perform DNA methylation
studies in DNA derived from UC-WBC as from UC-MNC, if
the use of homogeneous blood cells is not feasible. Nevertheless,
adjustment for WBC mixtures should always be applied in whole
blood EWAS to avoid confounding of underlyingWBCmixtures20.
Table 2. Top 10 DAVID GO Functional annotation clusters of HUVEC and
placental tDMR nearest genes
HUVEC
Annotation Cluster
Enrichment score
1. Embryonic morphogenesis 8.4
2. Negative regulation of gene expression 8.4
3. Positive regulation of gene expression 8.3
4. Cell motility 7.6
5. Vascular development and morphogenesis 7.1
6. Embryonic development 7.1
7. Haematopoiesis 7.0
8. Inflammatory response 6.7
9. Bone development 5.7
10. Cell adhesion 5.1
Placenta Annotation cluster
enrichment score
1. Embryonic development 13.9
2. Embryonic morphogenesis 12.9
3. Regionalisation 11.7
4. Negative regulation of gene expression 10.7
5. Embryonic organ development 9.3
6. Regulation of transcription 8.9
7. Embryonic development and morphogenesis 8.5
8. Positive regulation of gene expression 8.3
9. Cellular morphogenesis 8.3
10. Cell motility 7.2
tDMRs, tissue-specific differentially methylated regions; DAVID, Database for Annotation,
Visualization and Integrated Discovery; HUVEC, Human umbilical vein endothelial cell.
HUVEC and placental tDMRs were mapped to the nearest gene using Ensembl annotations
from UCSC database. Assigned Ensembl genes were uploaded to the DAVID tool to examine
possible enrichment of corresponding GO terms using the GO_BP_FAT annotation category.
Fisher’s exact test was applied to measure the gene enrichment of annotated GO terms of
the uploaded gene list, against the whole human genome list as a background. To focus on
the biology of the annotated GO terms, clusters of similar annotations were examined from
the DAVID Functional Annotation Clustering table tool. The clustering algorithm is based on
the hypothesis that similar annotations have similar gene members, resulting in a Group
Enrichment Score to rank their biological significance, which is based on the Fisher’s exact
p-values of each GO term within the cluster. The higher the enrichment score, the more the
enrichment is.
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Table 3. Top 10 Ingenuity networks and pathways of HUVEC and placental tDMR nearest genes
HUVEC canonical pathways −log p-value
1. Dendritic cell maturation 4.48
2. Antigen presentation pathway 4.48
3. T helper cell differentiation 4.48
4. Role of NFAT in regulation of the immune response 4.48
5. PKCθ signalling in T lymphocytes 4.48
6. iCOS-iCOSL signalling in T helper cells 4.48
7. OX40 signalling pathway 4.05
8. Hepatic fibrosis/hepatic stellate cell activation 4.04
9. Altered T cell and B cell signalling in rheumatoid arthritis 3.23
10. Allograft rejection signalling 3.11
HUVEC networks Score
1. Behaviour, reproductive system development and function, cellular function and maintenance 31/35
2. Cell-to-cell signalling and interaction, inflammatory response, lipid metabolism 31/35
3. Cellular function and maintenance, inflammatory response, digestive system development and function 29/34
4. Cellular movement, immune cell trafficking, cell morphology 27/33
5. Skeletal and muscular system development and function, embryonic development, organismal development 25/32
6. Infectious diseases, DNA replication, recombination, and repair, gene expression 25/32
7. Glomerular injury, organismal injury and abnormalities, renal fibrosis 25/32
8. Cell-to-cell signalling and interaction, haematological system development and function, immune cell trafficking 23/31
9. Cell signalling, molecular transport, vitamin and mineral metabolism 23/31
10. Connective tissue development and function, skeletal and muscular system development and function, tissue development 23/31
Placenta canonical pathways −log p-value
1. G protein-coupled receptor signalling 5.18
2. Glutamate receptor signalling 5.14
3. Neuropathic pain signalling in dorsal horn neurons 5.02
4. Human embryonic stem cell pluripotency 5.02
5. cAMP-mediated signalling 5.01
6. Regulation of the epithelial–mesenchymal transition pathway 5.01
7. Axonal guidance signalling 4.78
8. Transcriptional regulatory network in embryonic stem cells 4.43
9. Hepatic fibrosis/hepatic stellate cell activation 4.26
10. Antigen presentation pathway 3.38
Placenta networks Score
1. Cardiovascular disease, organismal injury and abnormalities, reproductive system disease 21/35
2. Cellular movement, cell morphology, cellular assembly and organisation 21/35
3. Cardiovascular disease, cellular movement, developmental disorder 21/35
4. Cell-to-cell signalling and interaction, cellular function and maintenance, embryonic development 21/35
5. Cell death and survival, cellular compromise, neurological disease 21/35
6. Cardiovascular system development and function, small molecule biochemistry, connective tissue development and function 19/34
7. Cell death and survival, infectious diseases, inflammatory disease 19/34
8. Haematological system development and function, organismal functions, cell-to-cell signalling and interaction 19/34
9. Cellular movement, cell death and survival, cardiovascular system development and function 19/34
10. Connective tissue disorders, cancer, gastrointestinal disease 19/34
tDMRs, tissue-specific differentially methylated regions; HUVEC, Human umbilical vein endothelial cells.
Ingenuity Pathway Analysis was performedwith the annotated DMP Ensembl gene lists with focus on canonical pathways and networks. Enriched canonical pathways were calculated using the
Fisher’s exact test and subjected to Benjamini–Hochberg procedure for controlling FDR (p< 0.05). Networks were generated based on network eligible molecules, which were encoded by our
DMP genes and also interact with other molecules in the Ingenuity Pathways Knowledge Base. A high score for a network indicates a more approximate fit between network eligible molecules
and the molecules that constitute the network, calculated using the right-tailed Fisher’s exact test.
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To this purpose, a cord blood-specific algorithm was recently
developed to estimate cell proportions44.
Our observations concerning UC-WBC seem in agreement
with the study of Wu et al., demonstrating significantly correlated
methylation levels within the same individuals for MNC andWBC
in adult peripheral blood, although these were measured by repeti-
tive element methylation levels in different assays45.
Enrichment analysis of the identified HUVEC and placental
tDMPs showed that tDMPs in general occur quite randomly rel-
ative to CpG density and genes. However, a strong depletion of
tDMPs in CpG islands and proximal promotors and a strong
enrichment in non-CpG islands was evident. Additionally, we
demonstrated HUVEC tDMP enrichment in gene body regions,
in agreement with Lokk et al.10. Gene bodies and non-CpG island
regions seem to be more tissue-specific and susceptible to variation
in DNA methylation and may therefore represent interesting
genomic regions for future epidemiologic epigenetic association
studies. This also suggests that we should focus less on the
concept of DNA methylation resulting in complete silencing of
transcription which is related to DNA methylation of promotor
regions. Methylation of gene bodies does in fact not block tran-
scription and is associated with transcription stimulation46.
Evidence emerges that CpG island methylation of promoter
regions, the main region of interest in previous work, is mostly
associated with long-term repression of gene expression
(Imprinting, X-chromosome inactivation i.a.), which is in line with
the shown depletion of tDMPs in CpG island proximal
promotors9,41,46.
GO functional annotations of the tDMRs demonstrated that
tissue-specific DNA methylation is involved in specific tissue-
related biological functions such as vascular development in
HUVEC, suggesting that DNA derived from HUVEC might be
more informative than from UC-WBC if one would be interested
in epigenetic involvement during prenatal vascular development.
Moreover, general biological functions and early developmental
processes were also observed in association with tDMR genes,
such as the regulation of gene expression, cellular function and
signalling and embryonic development. Both categories under-
line that the tissue-specific aspect should be considered in future
epigenetic association studies.
The Ingenuity Knowledge database validated most GO func-
tional annotations in revealing a broad spectrum of housekeeping
and embryonic development pathways. In addition, HUVEC
tDMR genes were annotated to immune response processes which
fit to the known immune cell adhesion and migration function of
endothelial cells17. This, however, also demonstrates that a certain
reference tissue might reveal corresponding tDMR genes, and one
could argue that the annotated immune response genes might in
fact be more attributable to our reference tissue UC-WBC than
to HUVEC-specific methylation. It should also be noted that
pathway enrichment analyses may be susceptible to bias due to
the design of the array, but we believe this is unlikely given the
strength of the enrichments consistent between DAVID and IPA47.
These data provide novel insights into the tissue specificity of
epigenome-wide DNA methylation in newborn and placental tis-
sues without confounding of postnatal exposures. The study was
performed in human tissues with a much larger sample size than
used in previous studies. A major strength of our study is the fact
that our samples are largely matched and therefore not confounded
by the potential influence of genetic variation on DNAmethylation.
Moreover, we standardised the tissue sampling and applied an opti-
mised tDMR identification technique. We therefore believe that our
findings support and contribute to the existing evidence demon-
strating the importance of tissue specificity in genome-wide DNA
methylation measurements.
The following concerns, however, need to be addressed. The
absence of expression data to validate our findings and the lack
of information on external validity are limitations of our study.
Furthermore, full replication of our analysis was not possible
because a comparable independent dataset with similar patients,
tissues and an almost full within-subject statistical study design
is not available. A strong correlation was however observed
between the estimates of the tissue effect in our own dataset and
Δβ methylation differences of HUVEC and placenta versus UC-
WBC of three independent datasets, suggesting partial replication
of our tDMPs (Supplementary Fig. S7). Moreover, our findings
could have been more relevant with the use of homogeneous cell
types of UCB and placental tissue, thereby avoiding any con-
founding of methylation differences due to underlying cell mixture
differences48,49. However, upon examination of the potential influ-
ence of underlying cell variation in UC-WBC and placental tissue
on our model, we did see a high correlation with and without
adjusting for cell heterogeneity, suggesting that the effect was mar-
ginal. A minor limitation is that we did not exclude the published
list of potential cross-reactive probes that are present on the array,
prior to further analysis50. However, given the number of cross-
reactive probes in comparison to the number of identified loci,
the effect will be very limited. Although we initially intended to
obtain all tissues from each patient, due to logistic reasons, it
appeared not feasible to perform a full within-subject analysis.
The collection of sufficient blood in cord blood collection bags
for UC-MNC isolation appeared extremely challenging. This
seemed a result of random factors, such as stressful deliveries, cae-
sarean sections or night shifts, but did not seem systematic. The
majority of study subjects were eventually overlapping in the com-
parisons between UC-WBC versus placenta (24 out of 25 subjects
in each group) and UC-WBC versus HUVEC (23 out of 25 subjects
in each group), but the UC-MNC group only shares one patient
with the UC-WBC. Fortunately, this resulted in maternal and fetal
characteristics that were almost isogenic and thus highly compa-
rable between all different tissue groups (Table 1). However, this
does not exclude some residual confounding based on genetic
variation, especially in the UC-MNC analysis.
Further research with repeated measurements is needed to gain
insights in themaintenance and stability of tissue-specific methyla-
tion differences throughout pregnancy and postnatal life, which
may increase or decrease due to accumulating environmental
exposures, ageing in general and stochastically51. Also, the degree
of correlation between tissue-specific epigenetic programming and
the possibility to observe effects of environmental exposures on
epigenetic features remains to be elucidated.
Conclusions
We demonstrated an extensive amount of genome-wide HUVEC
and placental tDMRs in comparison to UC-WBC. This underlines
the relevance of tissue-specific approaches in future epigenetic
association studies or the use of a profound and validated repre-
sentative tissue for a certain disease of interest, if available.
Especially, the potentially limited predictive value of extra-
embryonic placental tissue on epigenetic programming in fetal
tissues should be considered.
We herewith provide a relevant dataset of paired, tissue-
specific, genome-wide methylation measurements in newborn
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tissues. These, especially our novel HUVEC data, can serve as
additional reference methylomes for other investigators. Further
validation in functional studies is needed to establish the usability
of this data in future epigenetic epidemiological studies.
Supplementary material. For supplementary material for this article, please
visit https://doi.org/10.1017/S2040174420000136
Availability of data and material. The datasets generated during the current
study are available in the GEO repository with accession number GSE103253.
Any additional patient characteristics will be made available for others, upon
reasonable request, addressing the corresponding author.
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Appendix 1
Data collection
Immediately after delivery of the newborn, UCB samples from
the umbilical vein were collected in anticoagulant vacutainer
tubes (ethylenediaminetetraacetic acid) and cord blood collec-
tion bags containing 21-ml anticoagulant citrate-phosphate-
dextrose solution with the placenta still in situ. The complete
umbilical cord was cut at the placental insertion and immedi-
ately stored in umbilical cord buffer (HBSS with 1% penicillin/
streptomycin) at 4–8 °C until further HUVEC isolation within
24 h after delivery. Umbilical cord and placental samples were
collected within 10 min after delivery of the placenta. Placental
samples of 0.5 cm3 were taken from the fetal side of the villi at
four different sites in a 3-cm radius around the umbilical cord
insertion, after carefully removing the membranes and 2 mm
of the top placental layer. After washing in phosphate-buffered
saline (PBS) solution to remove maternal blood, placental
samples were snap-frozen in liquid nitrogen and stored at
−80 °C until DNA extraction. All samples were collected by
trained researchers.
UCB processing
UCB vacutainer tubes and cord blood collection bags were stored
at 4–8 °C and processed within 48 h after delivery. Total UC-WBC
were isolated after centrifugation of the vacutainer tubes. UC-
MNC represent a subgroup of UC-WBC and were obtained from
the cord blood collection bags using Ficoll gradient centrifugation
to remove granulocytes from the total WBC fraction. The UC-
WBC and MNC pellets were stored at −80 °C until DNA
extraction.
HUVEC isolation
The umbilical cord vein was connected to infusion tubes on both
extremes and rinsed with cord buffer. Once all remaining UCBwas
removed, the umbilical vein was filled with collagenase solution
(1 mg/ml) and incubated for 15 min in a PBS water bath at
37 °C. Detached HUVEC were obtained in suspension and further
purified by magnetic-activated cell separation (MACS) with
CD146 MACS MicroBeads (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany). PBS-washed HUVEC pellets were snap-fro-
zen in liquid nitrogen and stored at −80 °C until DNA extraction.
We assessed the cell purity of the first obtained HUVEC by count-
ing them microscopically. It was observed that a cell purity of
>95% was achieved, which we considered as sufficient for further
analyses.
DNA extraction
Thawed UC-WBC and UC-MNC pellets were subjected to eryth-
rocyte lysis by use of an Erythrocyte Lysis Buffer (Qiagen, Hilden,
Germany), following manufacturer’s protocols. Thirty milligrams
of frozen placental tissue were grinded manually on dry ice using a
tissue grinder. The placental powder was immediately added to a
cell lysis buffer and stored at −80 °C until further processing.
Subsequently, genomic DNA was extracted from all tissues using
the Allprep DNA/RNA isolation mini kit (Qiagen, Hilden,
Germany), according to manufacturer’s instructions.
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